NCT00682695 Genetic and Environmental Risk Factors for Hemorrhagic Stroke
| NCT ID | NCT00682695 |
| Status | Recruiting |
| Phase | — |
| Sponsor | State University of New York at Buffalo |
| Condition | Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2025-01-01 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to find risk factors for hemorrhagic stroke.
Eligibility Criteria
Inclusion Criteria: * Age 18 or older * Resident (6 months or longer) within the recruitment center * Fulfillment of the criteria for spontaneous ICH * No evidence of trauma, brain tumor/metastases or infectious processes as a cause of the hemorrhage * Ability of the patient or legal representative to provide consent for an interview, blood pressure determinations and DNA sampling Exclusion Criteria: * N/A
Contact & Investigator
Daniel Woo, MD
PRINCIPAL INVESTIGATOR
University of Cincinnati
Frequently Asked Questions
Who can join the NCT00682695 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00682695 currently recruiting?
Yes, NCT00682695 is actively recruiting participants. Contact the research team at Lee.gilkerson@uc.edu for enrollment information.
Where is the NCT00682695 trial being conducted?
This trial is being conducted at Chicago, United States, Louisville, United States, Baltimore, United States, Boston, United States and 3 additional locations.
Who is sponsoring the NCT00682695 clinical trial?
NCT00682695 is sponsored by State University of New York at Buffalo. The principal investigator is Daniel Woo, MD at University of Cincinnati. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.